<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01803074</url>
  </required_header>
  <id_info>
    <org_study_id>206739</org_study_id>
    <secondary_id>2012-004124-38</secondary_id>
    <secondary_id>AI468-002</secondary_id>
    <nct_id>NCT01803074</nct_id>
  </id_info>
  <brief_title>Study to Evaluate a HIV Drug for the Treatment of HIV Infection</brief_title>
  <official_title>Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to study the safety and tolerability of a HIV drug and
      to evaluate a decrease of HIV-1 virus level in blood after treatments in HIV-1 infected
      patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Masking: Open-Part B. Double Blind-Parts A and C

      Gender: Both female and male participants for Parts A and C. Male participants for Part B.

      HIV = Human Immunodeficiency Virus RNA = Ribonucleic acid
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2013</start_date>
  <completion_date type="Actual">November 29, 2014</completion_date>
  <primary_completion_date type="Actual">November 29, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Plasma Log10 HIV-1 Ribonucleic Acid (RNA) Levels From Baseline to Day 11</measure>
    <time_frame>Baseline (Day 1) and Day 11 after the final dose with BMS-955176</time_frame>
    <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Change in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 monotherapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) - Part A and C</measure>
    <time_frame>Pre-dose Day 1 and Day 10</time_frame>
    <description>Time to reach the maximum plasma concentration was directly determined from concentration time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), and Discontinuations Due to AEs During the Study</measure>
    <time_frame>Day 1 to end of the study (Day 42)</time_frame>
    <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Decline From Baseline in Log10 HIV-1 RNA - Part A and C</measure>
    <time_frame>Baseline (Day 1) up to Day 24</time_frame>
    <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Maximum decline from Baseline in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Decline From Baseline in Log10 HIV-1 RNA - Part B</measure>
    <time_frame>Baseline (Day 1) up to Day 42</time_frame>
    <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Maximum decline from Baseline in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Decline in Log 10 HIV-1 RNA - Part A and C</measure>
    <time_frame>Baseline (Day 1) up to Day 24</time_frame>
    <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Time to maximum decline in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Decline in Log 10 HIV-1 RNA - Part B</measure>
    <time_frame>Baseline (Day 1) up to Day 42</time_frame>
    <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Time to maximum decline in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Counts - Part A and C</measure>
    <time_frame>Baseline (Day 1) up to Day 24</time_frame>
    <description>Change in the CD4+ and CD8+ cell counts from Baseline were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 + ATV or BMS-955176 + ATV + RTV therapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Counts - Part B</measure>
    <time_frame>Baseline (Day 1) up to Day 42</time_frame>
    <description>Change in the CD4+ and CD8+ cell counts from Baseline were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 + ATV or BMS-955176 + ATV + RTV therapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Percent - Part A and C</measure>
    <time_frame>Baseline (Day 1) up to Day 24</time_frame>
    <description>Percent Change in the CD4+ and CD8+ cell counts from Baseline were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 + ATV or BMS-955176 + ATV + RTV therapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Percent - Part B</measure>
    <time_frame>Baseline (Day 1) up to Day 42</time_frame>
    <description>Percent Change in the CD4+ and CD8+ cell counts from Baseline were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 + ATV or BMS-955176 + ATV + RTV therapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) - Part B</measure>
    <time_frame>Pre-dose Day 1 and Day 28</time_frame>
    <description>Tmax was directly determined from concentration time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentrations (Cmax) - Part A and C</measure>
    <time_frame>Pre-dose Day 1 and Day 10</time_frame>
    <description>Cmax was defined as the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration 24 Hours Post-Dose (C24) - Part A and C</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>C24 was defined as the plasma concentration of BMS-955176 at 24 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentrations (Cmax) - Part B</measure>
    <time_frame>Pre-dose Day 1 and Day 28</time_frame>
    <description>Cmax was defined as the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration 24 Hours Post-Dose (C24) - Part B</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>C24 was defined as the plasma concentration of BMS-955176 at 24 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration - Time Curve Over the Dosing Interval (AUC([Tau]) - Part A and C</measure>
    <time_frame>Pre-dose Day 1 and Day 10</time_frame>
    <description>AUC(tau) was defined as the area under the plasma concentration - time curve over the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration - Time Curve Over the Dosing Interval (AUC[Tau]) - Part B</measure>
    <time_frame>Pre-dose Day 1 and Day 28</time_frame>
    <description>AUC(tau) was defined as the area under the plasma concentration - time curve over the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index (AI): Part A and C</measure>
    <time_frame>Baseline and Day 10</time_frame>
    <description>Accumulation index was calculated by dividing the AUC(tau) or Cmax or C24 of BMS-955176 on Day 10 by the AUC(TAU) or Cmax or C24, respectively, of BMS-955176 on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance: Part A and C</measure>
    <time_frame>Baseline (Day 1) to Day 10</time_frame>
    <description>Apparent total body clearance was derived by non-compartmental methods, using a validated pharmacokinetic (PK) analysis program: KineticaTM 5.0 within eToolbox (version 2.7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Fluctuation (DF): Part A and C</measure>
    <time_frame>Baseline (Day 1) to Day 10</time_frame>
    <description>DF was calculated as the difference between Cmax and Cmin divided by Css-avg. DF was derived by non-compartmental methods, using a validated pharmacokinetic (PK) analysis program: KineticaTM 5.0 within eToolbox (version 2.7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Observed Plasma Concentration at Steady State (Css-avg): Part A and C</measure>
    <time_frame>Baseline (Day 1) to Day 10</time_frame>
    <description>Css-avg was calculated by the quotient of AUC(TAU) and the dosing interval (24 h). Css-avg was derived by non-compartmental methods, using a validated pharmacokinetic (PK) analysis program: KineticaTM 5.0 within eToolbox (version 2.7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Half-life: Part A and C</measure>
    <time_frame>Baseline (Day 1) to Day 10</time_frame>
    <description>Half-life of the terminal log-linear phase, (T-half), was calculated as natural logarithm of 2 (ln2)/λ, where λ is the absolute value of the slope of the terminal log-linear phase. T-half was derived by non-compartmental methods, using a validated pharmacokinetic (PK) analysis program: KineticaTM 5.0 within eToolbox (version 2.7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Grade 3/4 Laboratory Abnormalities From Baseline</measure>
    <time_frame>Day 1 to up to end of the study (Day 42)</time_frame>
    <description>Laboratory abnormalities were determined and graded using the Division of Acquired Immune Deficiency Syndrome (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0, December 2004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Heart Rate</measure>
    <time_frame>Day 1 to end of the study (Day 42)</time_frame>
    <description>Heart rate was measured after the participants had been seated quietly for at least 5 minutes. Criteria used to determine heart rate that are outside of a pre-specified range, where changes from Baseline are based on matched postural positions and are calculated as parameter value - Baseline parameter value: Value &gt;100 and change from Baseline &gt; 30, or Value &lt; 55 and change from Baseline &lt; -15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)</measure>
    <time_frame>Day 1 to end of the study (Day 42)</time_frame>
    <description>Participants with out of range ECG intervals were summarized. Criteria used to determine ECG results that are outside of a pre-specified range: PR (milliseconds [msec]): Value &gt;200; QRS (msec): Value &gt;120; QT (msec): Value &gt;500 or change from Baseline &gt;30; corrected QT interval Fridericia's formula (QTcF) (msec): Value &gt;450 or change from Baseline &gt;30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Changes in Physical Examination</measure>
    <time_frame>Day 1 to end of the study (Day 42)</time_frame>
    <description>Participants with abnormal changes in physical examination is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Day 1 to end of the study (Day 42)</time_frame>
    <description>Systolic BP (millimeter of mercury [mmHg]): value &gt;140 and change from Baseline &gt;20, or value &lt;90 and change from Baseline &lt;-20; Diastolic BP (mmHg): value &gt;90 and change from Baseline &gt;10, or value &lt;55 and change from Baseline &lt;-10.</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Part A-Group 1: BMS-955176 (5 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 5 mg solution by mouth once daily for 10 days
OR
Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A-Group 2: BMS-955176 (10 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 10 mg solution by mouth once daily for 10 days
OR
Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A-Group 3: BMS-955176 (20 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 20 mg solution by mouth once daily for 10 days
OR
Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A-Group 4: BMS-955176 (40 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 40 mg solution by mouth once daily for 10 days
OR
Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B-Group 5: BMS-955176 + Atazanavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 40 mg solution by mouth once daily for 28 days
Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 40 mg solution by mouth once daily for 28 days
Atazanavir 1 x 300 mg capsules by mouth once daily for 28 days
Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atazanavir 1 x 300 mg capsule by mouth once daily for 28 days
Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days
Tenofovir 1 x 300 mg tablet by mouth once daily for 28 days
Emtricitabine 1 x 200 mg capsule once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C-Group 8: BMS-955176 (40 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 40 mg solution by mouth once daily for 10 days
OR
Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A-Group 9: BMS-955176 (80 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 80 mg solution by mouth once daily for 10 days
OR
Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A-Group 10: BMS-955176 (120 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 120 mg solution by mouth once daily for 10 days
OR
Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A-Group 11 (Optional): BMS-955176 (≤120 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 ≤120 mg solution by mouth once daily for 14 days
OR
Placebo matching with BMS-955176 0 mg solution by mouth once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 80 mg solution by mouth once daily for 28 days
Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C-Group 13: BMS-955176 (120 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-955176 120 mg solution by mouth once daily for 10 days
OR
Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-955176</intervention_name>
    <description>BMS-955176</description>
    <arm_group_label>Part A-Group 10: BMS-955176 (120 mg) or Placebo</arm_group_label>
    <arm_group_label>Part A-Group 11 (Optional): BMS-955176 (≤120 mg) or Placebo</arm_group_label>
    <arm_group_label>Part A-Group 1: BMS-955176 (5 mg) or Placebo</arm_group_label>
    <arm_group_label>Part A-Group 2: BMS-955176 (10 mg) or Placebo</arm_group_label>
    <arm_group_label>Part A-Group 3: BMS-955176 (20 mg) or Placebo</arm_group_label>
    <arm_group_label>Part A-Group 4: BMS-955176 (40 mg) or Placebo</arm_group_label>
    <arm_group_label>Part A-Group 9: BMS-955176 (80 mg) or Placebo</arm_group_label>
    <arm_group_label>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</arm_group_label>
    <arm_group_label>Part B-Group 5: BMS-955176 + Atazanavir</arm_group_label>
    <arm_group_label>Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir</arm_group_label>
    <arm_group_label>Part C-Group 13: BMS-955176 (120 mg) or Placebo</arm_group_label>
    <arm_group_label>Part C-Group 8: BMS-955176 (40 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching with BMS-955176</intervention_name>
    <description>Placebo matching with BMS-955176</description>
    <arm_group_label>Part A-Group 10: BMS-955176 (120 mg) or Placebo</arm_group_label>
    <arm_group_label>Part A-Group 11 (Optional): BMS-955176 (≤120 mg) or Placebo</arm_group_label>
    <arm_group_label>Part A-Group 1: BMS-955176 (5 mg) or Placebo</arm_group_label>
    <arm_group_label>Part A-Group 2: BMS-955176 (10 mg) or Placebo</arm_group_label>
    <arm_group_label>Part A-Group 3: BMS-955176 (20 mg) or Placebo</arm_group_label>
    <arm_group_label>Part A-Group 4: BMS-955176 (40 mg) or Placebo</arm_group_label>
    <arm_group_label>Part A-Group 9: BMS-955176 (80 mg) or Placebo</arm_group_label>
    <arm_group_label>Part C-Group 13: BMS-955176 (120 mg) or Placebo</arm_group_label>
    <arm_group_label>Part C-Group 8: BMS-955176 (40 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>Atazanavir</description>
    <arm_group_label>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</arm_group_label>
    <arm_group_label>Part B-Group 5: BMS-955176 + Atazanavir</arm_group_label>
    <arm_group_label>Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir</arm_group_label>
    <arm_group_label>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir</description>
    <arm_group_label>Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir</arm_group_label>
    <arm_group_label>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Tenofovir</description>
    <arm_group_label>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
    <description>Emtricitabine</description>
    <arm_group_label>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Age 18-55 years inclusive

          -  Men and women: (Parts A and C); men only (Part B)

          -  Women of childbearing potential (WOCBP) must not be pregnant and nursing

          -  BMI: 18.0-35.0 kg/m2

          -  Subjects are infected with HIV-1 (clades B or C) and meet following criteria at the
             screening:

             i) Plasma HIV-1 RNA ≥5,000 copies/mL; ii) Antiretroviral treatment naive (defined as
             &lt;1 week of ARV treatment) or ART-experienced (protease inhibitor and/or maturation
             inhibitor naive); iii) Subjects are not eligible for HIV-1 treatment based on the
             United States Department of Health and Human Services Panel on Antiretroviral
             Guidelines for Adults and Adolescents or have declined initiation of cART iv) CD4+
             lymphocyte measurement ≥200 cells/μL; v) In Parts A and B, all subjects are infected
             with HIV-1 clade B vi) In Part C, all subjects are infected with HIV-1 clade C

        Exclusion Criteria:

          -  History of genotypic and/or phenotypic drug resistance testing showing resistance to
             protease inhibitors

          -  Any significant acute or chronic medical illness which is not stable or is not
             controlled with medication or not consistent with HIV-1 infection

          -  Receive antiretroviral treatment within 12 weeks prior to screening

          -  Currently co-infected with hepatitis C or hepatitis B

          -  Previously received an HIV maturation inhibitor or HIV protease inhibitor

          -  Current or recent (within 3 months of study drug administration) gastrointestinal
             disease

          -  Any major surgery within 4 weeks of study drug administration

          -  Acute diarrhea lasting ≥1 day, within 3 weeks prior to randomization

          -  Subjects with history of Gilbert's syndrome

          -  Subjects previously received an HIV maturation inhibitor or HIV protease inhibitor

          -  A personal history of clinically relevant cardiac disease, symptomatic or asymptomatic
             arrhythmias, syncopal episodes, or additional risk factors for torsades de pointes. A
             personal or family history of long QT syndrome

          -  Patients who are unwilling to practice adequate infection protection during and after
             study participation to minimize potential for spread of HIV infection, including HIV
             which may have developed resistance to HIV maturation inhibitor and/or ATV

          -  Any gastrointestinal surgery that could impact upon the absorption of study drug

          -  Smoking &gt;10 cigarettes per day

          -  PR ≥210 msec; QRS ≥120 msec; QT ≥500 msec; and QTcF ≥470 msec for women and ≥450 msec
             for men

          -  Evidence of second or third degree heart block prior to study drug

          -  Absolute Neutrophil Count &lt;(ANC) 0.7 x lower limit of normal (LLN)

          -  Hemoglobin &lt;0.8 x LLN

          -  Alanine aminotransferase (ALT) &gt;1.25 x upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) &gt;1.25 x ULN

          -  Total Bilirubin &gt;1.25 x ULN

          -  Creatinine clearance &lt;60 mL/mim

          -  Positive urine screen for drugs of abuse without a valid prescription (subjects
             positive for cannabinoids and/or amphetamines will be included)

          -  Positive blood screen for hepatitis C virus (HCV) RNA, hepatitis B surface antigen
             (consistent with active or chronic hepatitis B), or HIV-2 antibody

          -  History of any significant drug allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 1, 2013</study_first_submitted>
  <study_first_submitted_qc>March 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2013</study_first_posted>
  <results_first_submitted>January 28, 2019</results_first_submitted>
  <results_first_submitted_qc>November 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2019</results_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>BMS-955176</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 3 centers in 3 countries (1 in Germany, 1 in the United Kingdom, 1 in South Africa) from 04-April-2013 to 29-November-2014.</recruitment_details>
      <pre_assignment_details>Participants screened were 191 of which 84 were screen failures (Participant withdrew consent: 3, Pregnancy: 3, Participant no longer meets study criteria: 73, Not according to participant’s schedule: 1, Not included since cohort was closed: 3 and back up participant: 1). Only 107 participants (Part A: 60; Part B: 28; and Part C: 19) were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A-Group 1: BMS-955176 (5 mg)</title>
          <description>Participants infected with Human Immunodeficiency Virus Type-1 (HIV-1) clade B were treated with 5 milligrams (mg) BMS-955176 as oral suspension, once daily (QD) from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="P2">
          <title>Part A-Group 2: BMS-955176 (10 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="P3">
          <title>Part A-Group 3: BMS-955176 (20 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="P4">
          <title>Part A-Group 4: BMS-955176 (40 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="P5">
          <title>Part A-Group 9: BMS-955176 (80 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="P6">
          <title>Part A-Group 10: BMS-955176 (120 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="P7">
          <title>Placebo Clade B</title>
          <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="P8">
          <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
          <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
        </group>
        <group group_id="P9">
          <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
          <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
        </group>
        <group group_id="P10">
          <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
          <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
        </group>
        <group group_id="P11">
          <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
          <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
        </group>
        <group group_id="P12">
          <title>Part C-Group 8: BMS-955176 (40 mg)</title>
          <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="P13">
          <title>Part C-Group 13: BMS-955176 (120 mg)</title>
          <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="P14">
          <title>Placebo Clade C</title>
          <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Part A (HIV-1 Clade B)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2: Part B (HIV-1 Clade B)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3: Part C (HIV-1 Clade C Only)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="8"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="8"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A-Group 1: BMS-955176 (5 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="B2">
          <title>Part A-Group 2: BMS-955176 (10 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="B3">
          <title>Part A-Group 3: BMS-955176 (20 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="B4">
          <title>Part A-Group 4: BMS-955176 (40 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="B5">
          <title>Part A-Group 9: BMS-955176 (80 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="B6">
          <title>Part A-Group 10: BMS-955176 (120 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="B7">
          <title>Placebo Clade B</title>
          <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="B8">
          <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
          <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
        </group>
        <group group_id="B9">
          <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
          <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
        </group>
        <group group_id="B10">
          <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
          <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
        </group>
        <group group_id="B11">
          <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
          <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
        </group>
        <group group_id="B12">
          <title>Part C-Group 8: BMS-955176 (40 mg)</title>
          <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="B13">
          <title>Part C-Group 13: BMS-955176 (120 mg)</title>
          <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="B14">
          <title>Placebo Clade C</title>
          <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="8"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="4"/>
            <count group_id="B11" value="8"/>
            <count group_id="B12" value="8"/>
            <count group_id="B13" value="7"/>
            <count group_id="B14" value="4"/>
            <count group_id="B15" value="107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" spread="8.73"/>
                    <measurement group_id="B2" value="37.5" spread="11.07"/>
                    <measurement group_id="B3" value="33.3" spread="7.19"/>
                    <measurement group_id="B4" value="39.5" spread="8.09"/>
                    <measurement group_id="B5" value="36.3" spread="11.23"/>
                    <measurement group_id="B6" value="38.0" spread="9.49"/>
                    <measurement group_id="B7" value="36.3" spread="7.12"/>
                    <measurement group_id="B8" value="33.0" spread="7.21"/>
                    <measurement group_id="B9" value="36.3" spread="9.24"/>
                    <measurement group_id="B10" value="32.8" spread="10.21"/>
                    <measurement group_id="B11" value="34.3" spread="6.80"/>
                    <measurement group_id="B12" value="33.6" spread="7.80"/>
                    <measurement group_id="B13" value="35.4" spread="9.59"/>
                    <measurement group_id="B14" value="35.3" spread="8.54"/>
                    <measurement group_id="B15" value="36.1" spread="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="7"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian/Alaska</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Plasma Log10 HIV-1 Ribonucleic Acid (RNA) Levels From Baseline to Day 11</title>
        <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Change in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 monotherapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
        <time_frame>Baseline (Day 1) and Day 11 after the final dose with BMS-955176</time_frame>
        <population>All Treated Subjects Population comprised of all participants who had received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O9">
            <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
            <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O10">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O11">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O12">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O13">
            <title>Placebo Clade B</title>
            <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O14">
            <title>Placebo Clade C</title>
            <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Log10 HIV-1 Ribonucleic Acid (RNA) Levels From Baseline to Day 11</title>
          <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Change in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 monotherapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
          <population>All Treated Subjects Population comprised of all participants who had received at least one dose of study drug.</population>
          <units>Log10 copies per milliliter (c/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.138" spread="0.1281"/>
                    <measurement group_id="O2" value="-0.567" spread="0.5845"/>
                    <measurement group_id="O3" value="-0.889" spread="0.6582"/>
                    <measurement group_id="O4" value="-1.279" spread="0.4596"/>
                    <measurement group_id="O5" value="-1.339" spread="0.29"/>
                    <measurement group_id="O6" value="-1.326" spread="0.3855"/>
                    <measurement group_id="O7" value="-1.216" spread="0.4366"/>
                    <measurement group_id="O8" value="-1.431" spread="0.2967"/>
                    <measurement group_id="O9" value="-1.544" spread="0.4155"/>
                    <measurement group_id="O10" value="-1.521" spread="0.2651"/>
                    <measurement group_id="O11" value="-1.29" spread="0.3376"/>
                    <measurement group_id="O12" value="-0.938" spread="0.6897"/>
                    <measurement group_id="O13" value="0.118" spread="0.5277"/>
                    <measurement group_id="O14" value="-0.172" spread="0.7876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) - Part A and C</title>
        <description>Time to reach the maximum plasma concentration was directly determined from concentration time data.</description>
        <time_frame>Pre-dose Day 1 and Day 10</time_frame>
        <population>Pharmacokinetic Population comprised of all participants who received any study medication and had any available concentration-time data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) - Part A and C</title>
          <description>Time to reach the maximum plasma concentration was directly determined from concentration time data.</description>
          <population>Pharmacokinetic Population comprised of all participants who received any study medication and had any available concentration-time data.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1.5" upper_limit="6"/>
                    <measurement group_id="O2" value="2.51" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O3" value="3" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O4" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O5" value="3.5" lower_limit="3" upper_limit="4"/>
                    <measurement group_id="O6" value="3" lower_limit="1.5" upper_limit="6"/>
                    <measurement group_id="O7" value="3.5" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O8" value="3.53" lower_limit="2" upper_limit="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="1.5" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="3" upper_limit="16"/>
                    <measurement group_id="O4" value="3" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O5" value="3" lower_limit="1.5" upper_limit="4.02"/>
                    <measurement group_id="O6" value="2.5" lower_limit="1.5" upper_limit="3.87"/>
                    <measurement group_id="O7" value="3" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O8" value="3" lower_limit="1.55" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), and Discontinuations Due to AEs During the Study</title>
        <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug.</description>
        <time_frame>Day 1 to end of the study (Day 42)</time_frame>
        <population>All Treated Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O9">
            <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
            <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O10">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O11">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O12">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O13">
            <title>Placebo Clade B</title>
            <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O14">
            <title>Placebo Clade C</title>
            <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), and Discontinuations Due to AEs During the Study</title>
          <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug.</description>
          <population>All Treated Subjects Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="7"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="9"/>
                    <measurement group_id="O14" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Decline From Baseline in Log10 HIV-1 RNA - Part A and C</title>
        <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Maximum decline from Baseline in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
        <time_frame>Baseline (Day 1) up to Day 24</time_frame>
        <population>All Treated Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Clade B</title>
            <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O10">
            <title>Placebo Clade C</title>
            <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Decline From Baseline in Log10 HIV-1 RNA - Part A and C</title>
          <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Maximum decline from Baseline in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
          <population>All Treated Subjects Population.</population>
          <units>Log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.498" lower_limit="-0.78" upper_limit="-0.22"/>
                    <measurement group_id="O2" value="-0.976" lower_limit="-1.76" upper_limit="-0.64"/>
                    <measurement group_id="O3" value="-1.115" lower_limit="-2.12" upper_limit="-0.13"/>
                    <measurement group_id="O4" value="-1.701" lower_limit="-1.88" upper_limit="-0.93"/>
                    <measurement group_id="O5" value="-1.555" lower_limit="-1.82" upper_limit="-1.04"/>
                    <measurement group_id="O6" value="-1.654" lower_limit="-2.07" upper_limit="-0.83"/>
                    <measurement group_id="O7" value="-1.352" lower_limit="-2.03" upper_limit="-1.04"/>
                    <measurement group_id="O8" value="-1.257" lower_limit="-2.02" upper_limit="-0.7"/>
                    <measurement group_id="O9" value="-0.381" lower_limit="-1.46" upper_limit="0.56"/>
                    <measurement group_id="O10" value="-0.419" lower_limit="-1.21" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Decline From Baseline in Log10 HIV-1 RNA - Part B</title>
        <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Maximum decline from Baseline in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
        <time_frame>Baseline (Day 1) up to Day 42</time_frame>
        <population>All Treated Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
            <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Decline From Baseline in Log10 HIV-1 RNA - Part B</title>
          <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Maximum decline from Baseline in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
          <population>All Treated Subjects Population.</population>
          <units>Log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.858" lower_limit="-2.37" upper_limit="-1.49"/>
                    <measurement group_id="O2" value="-2.202" lower_limit="-3.52" upper_limit="-1.24"/>
                    <measurement group_id="O3" value="-2.39" lower_limit="-3.04" upper_limit="-1.83"/>
                    <measurement group_id="O4" value="-2.228" lower_limit="-2.68" upper_limit="-1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Decline in Log 10 HIV-1 RNA - Part A and C</title>
        <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Time to maximum decline in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
        <time_frame>Baseline (Day 1) up to Day 24</time_frame>
        <population>All Treated Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Clade B</title>
            <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O10">
            <title>Placebo Clade C</title>
            <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Decline in Log 10 HIV-1 RNA - Part A and C</title>
          <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Time to maximum decline in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
          <population>All Treated Subjects Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" lower_limit="72" upper_limit="433.4"/>
                    <measurement group_id="O2" value="216" lower_limit="48" upper_limit="553.5"/>
                    <measurement group_id="O3" value="203.9" lower_limit="168" upper_limit="288.1"/>
                    <measurement group_id="O4" value="240.15" lower_limit="120.1" upper_limit="312.1"/>
                    <measurement group_id="O5" value="204" lower_limit="168" upper_limit="384.6"/>
                    <measurement group_id="O6" value="240.2" lower_limit="216" upper_limit="288.3"/>
                    <measurement group_id="O7" value="228.05" lower_limit="192" upper_limit="384.6"/>
                    <measurement group_id="O8" value="215.8" lower_limit="120" upper_limit="312"/>
                    <measurement group_id="O9" value="216.2" lower_limit="24" upper_limit="433.8"/>
                    <measurement group_id="O10" value="132.05" lower_limit="23.9" upper_limit="786.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Decline in Log 10 HIV-1 RNA - Part B</title>
        <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Time to maximum decline in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
        <time_frame>Baseline (Day 1) up to Day 42</time_frame>
        <population>All Treated Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
            <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Decline in Log 10 HIV-1 RNA - Part B</title>
          <description>Antiviral activity of BMS-955176 was estimated by measuring the plasma HIV-1 RNA levels in the HIV-1 infected participants. Time to maximum decline in the plasma HIV-1 RNA levels were measured in the participants infected with HIV-1 clade B and C. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
          <population>All Treated Subjects Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="624" lower_limit="360" upper_limit="816"/>
                    <measurement group_id="O2" value="636.05" lower_limit="216" upper_limit="816.9"/>
                    <measurement group_id="O3" value="588" lower_limit="528" upper_limit="672.1"/>
                    <measurement group_id="O4" value="636.05" lower_limit="528" upper_limit="816.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Counts - Part A and C</title>
        <description>Change in the CD4+ and CD8+ cell counts from Baseline were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 + ATV or BMS-955176 + ATV + RTV therapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
        <time_frame>Baseline (Day 1) up to Day 24</time_frame>
        <population>All Treated Subjects Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Clade B</title>
            <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O10">
            <title>Placebo Clade C</title>
            <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Counts - Part A and C</title>
          <description>Change in the CD4+ and CD8+ cell counts from Baseline were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 + ATV or BMS-955176 + ATV + RTV therapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
          <population>All Treated Subjects Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Cells/microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.8" spread="88.37"/>
                    <measurement group_id="O2" value="14.6" spread="120.82"/>
                    <measurement group_id="O3" value="-70.1" spread="68.49"/>
                    <measurement group_id="O4" value="-23.6" spread="42.13"/>
                    <measurement group_id="O5" value="-43.8" spread="69.5"/>
                    <measurement group_id="O6" value="-56.7" spread="78.26"/>
                    <measurement group_id="O7" value="-53.7" spread="93.76"/>
                    <measurement group_id="O8" value="24.5" spread="57.58"/>
                    <measurement group_id="O9" value="-77.3" spread="91.05"/>
                    <measurement group_id="O10" value="18" spread="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-95" spread="301.52"/>
                    <measurement group_id="O2" value="-8.3" spread="236.48"/>
                    <measurement group_id="O3" value="-107.4" spread="264.26"/>
                    <measurement group_id="O4" value="-57.3" spread="126.25"/>
                    <measurement group_id="O5" value="-194.6" spread="182.3"/>
                    <measurement group_id="O6" value="-161.3" spread="203.01"/>
                    <measurement group_id="O7" value="-214.4" spread="390.13"/>
                    <measurement group_id="O8" value="-155.8" spread="56.55"/>
                    <measurement group_id="O9" value="-93.1" spread="138.52"/>
                    <measurement group_id="O10" value="-136.3" spread="224.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Counts - Part B</title>
        <description>Change in the CD4+ and CD8+ cell counts from Baseline were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 + ATV or BMS-955176 + ATV + RTV therapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
        <time_frame>Baseline (Day 1) up to Day 42</time_frame>
        <population>All Treated Subjects Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
            <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Counts - Part B</title>
          <description>Change in the CD4+ and CD8+ cell counts from Baseline were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 + ATV or BMS-955176 + ATV + RTV therapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
          <population>All Treated Subjects Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Cells/microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-133.2" spread="84.14"/>
                    <measurement group_id="O2" value="-106.4" spread="166.59"/>
                    <measurement group_id="O3" value="33" spread="144.79"/>
                    <measurement group_id="O4" value="-89" spread="35.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-442.8" spread="243.99"/>
                    <measurement group_id="O2" value="-466.1" spread="491.21"/>
                    <measurement group_id="O3" value="-216.3" spread="287.06"/>
                    <measurement group_id="O4" value="-147" spread="140.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Percent - Part A and C</title>
        <description>Percent Change in the CD4+ and CD8+ cell counts from Baseline were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 + ATV or BMS-955176 + ATV + RTV therapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
        <time_frame>Baseline (Day 1) up to Day 24</time_frame>
        <population>All Treated Subjects Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Clade B</title>
            <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O10">
            <title>Placebo Clade C</title>
            <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Percent - Part A and C</title>
          <description>Percent Change in the CD4+ and CD8+ cell counts from Baseline were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 + ATV or BMS-955176 + ATV + RTV therapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
          <population>All Treated Subjects Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="2.944"/>
                    <measurement group_id="O2" value="0.29" spread="2.215"/>
                    <measurement group_id="O3" value="-1.29" spread="5.057"/>
                    <measurement group_id="O4" value="0.86" spread="3.288"/>
                    <measurement group_id="O5" value="2.13" spread="3.399"/>
                    <measurement group_id="O6" value="0.29" spread="2.87"/>
                    <measurement group_id="O7" value="0.5" spread="3.017"/>
                    <measurement group_id="O8" value="3.17" spread="3.371"/>
                    <measurement group_id="O9" value="-0.22" spread="3.93"/>
                    <measurement group_id="O10" value="2.75" spread="3.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="2.401"/>
                    <measurement group_id="O2" value="0.43" spread="3.207"/>
                    <measurement group_id="O3" value="0" spread="6.325"/>
                    <measurement group_id="O4" value="1" spread="3.225"/>
                    <measurement group_id="O5" value="-0.25" spread="5.064"/>
                    <measurement group_id="O6" value="-2.29" spread="2.812"/>
                    <measurement group_id="O7" value="0" spread="1.871"/>
                    <measurement group_id="O8" value="-4.25" spread="3.775"/>
                    <measurement group_id="O9" value="1.75" spread="4.2"/>
                    <measurement group_id="O10" value="-1.33" spread="5.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Percent - Part B</title>
        <description>Percent Change in the CD4+ and CD8+ cell counts from Baseline were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 + ATV or BMS-955176 + ATV + RTV therapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
        <time_frame>Baseline (Day 1) up to Day 42</time_frame>
        <population>All Treated Subjects Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
            <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Percent - Part B</title>
          <description>Percent Change in the CD4+ and CD8+ cell counts from Baseline were measured in the participants infected with HIV-1 clade B and C who received BMS-955176 + ATV or BMS-955176 + ATV + RTV therapy. Baseline was Day 1. Change from Baseline was post-Baseline individual values minus Baseline values.</description>
          <population>All Treated Subjects Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.881"/>
                    <measurement group_id="O2" value="3.25" spread="3.105"/>
                    <measurement group_id="O3" value="4.75" spread="2.217"/>
                    <measurement group_id="O4" value="-0.75" spread="1.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.924"/>
                    <measurement group_id="O2" value="-6.25" spread="4.464"/>
                    <measurement group_id="O3" value="-3.75" spread="2.062"/>
                    <measurement group_id="O4" value="-1.25" spread="2.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) - Part B</title>
        <description>Tmax was directly determined from concentration time data.</description>
        <time_frame>Pre-dose Day 1 and Day 28</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) - Part B</title>
          <description>Tmax was directly determined from concentration time data.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" lower_limit="3" upper_limit="12"/>
                    <measurement group_id="O2" value="5.05" lower_limit="4" upper_limit="12"/>
                    <measurement group_id="O3" value="5" lower_limit="5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="6.02"/>
                    <measurement group_id="O3" value="4.5" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentrations (Cmax) - Part A and C</title>
        <description>Cmax was defined as the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
        <time_frame>Pre-dose Day 1 and Day 10</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentrations (Cmax) - Part A and C</title>
          <description>Cmax was defined as the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Nanogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.376" spread="37.6"/>
                    <measurement group_id="O2" value="201.498" spread="21.1"/>
                    <measurement group_id="O3" value="349.466" spread="23.2"/>
                    <measurement group_id="O4" value="791.317" spread="46.8"/>
                    <measurement group_id="O5" value="1155.448" spread="27.1"/>
                    <measurement group_id="O6" value="1515.389" spread="27.4"/>
                    <measurement group_id="O7" value="793.569" spread="21.2"/>
                    <measurement group_id="O8" value="1907.747" spread="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.778" spread="20.8"/>
                    <measurement group_id="O2" value="337.379" spread="20.9"/>
                    <measurement group_id="O3" value="705.073" spread="15.4"/>
                    <measurement group_id="O4" value="1476.166" spread="17.2"/>
                    <measurement group_id="O5" value="2466.447" spread="22.1"/>
                    <measurement group_id="O6" value="2809.671" spread="25.5"/>
                    <measurement group_id="O7" value="1560.122" spread="17.4"/>
                    <measurement group_id="O8" value="3377.967" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration 24 Hours Post-Dose (C24) - Part A and C</title>
        <description>C24 was defined as the plasma concentration of BMS-955176 at 24 hours post-dose.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration 24 Hours Post-Dose (C24) - Part A and C</title>
          <description>C24 was defined as the plasma concentration of BMS-955176 at 24 hours post-dose.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Nanogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.946" spread="28.4"/>
                    <measurement group_id="O2" value="79.002" spread="27.2"/>
                    <measurement group_id="O3" value="154.5" spread="23.7"/>
                    <measurement group_id="O4" value="286.268" spread="15.6"/>
                    <measurement group_id="O5" value="482.349" spread="34.3"/>
                    <measurement group_id="O6" value="624.745" spread="24.6"/>
                    <measurement group_id="O7" value="339.173" spread="30.1"/>
                    <measurement group_id="O8" value="865.867" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.642" spread="23.1"/>
                    <measurement group_id="O2" value="138.775" spread="34.1"/>
                    <measurement group_id="O3" value="325.934" spread="19.4"/>
                    <measurement group_id="O4" value="713.077" spread="21.9"/>
                    <measurement group_id="O5" value="1150.397" spread="31.5"/>
                    <measurement group_id="O6" value="1288.985" spread="26.8"/>
                    <measurement group_id="O7" value="779.438" spread="24.6"/>
                    <measurement group_id="O8" value="1691.306" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentrations (Cmax) - Part B</title>
        <description>Cmax was defined as the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
        <time_frame>Pre-dose Day 1 and Day 28</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentrations (Cmax) - Part B</title>
          <description>Cmax was defined as the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Nanogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="695.596" spread="9.52"/>
                    <measurement group_id="O2" value="770.975" spread="28.2"/>
                    <measurement group_id="O3" value="1493.336" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1667.817" spread="30.2"/>
                    <measurement group_id="O2" value="1852" spread="33.6"/>
                    <measurement group_id="O3" value="3159.181" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration 24 Hours Post-Dose (C24) - Part B</title>
        <description>C24 was defined as the plasma concentration of BMS-955176 at 24 hours post-dose.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration 24 Hours Post-Dose (C24) - Part B</title>
          <description>C24 was defined as the plasma concentration of BMS-955176 at 24 hours post-dose.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Nanogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462.312" spread="25"/>
                    <measurement group_id="O2" value="520.048" spread="27.7"/>
                    <measurement group_id="O3" value="899.364" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1099.313" spread="37"/>
                    <measurement group_id="O2" value="1163.177" spread="30.9"/>
                    <measurement group_id="O3" value="2010.679" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under The Plasma Concentration - Time Curve Over the Dosing Interval (AUC([Tau]) - Part A and C</title>
        <description>AUC(tau) was defined as the area under the plasma concentration - time curve over the dosing interval.</description>
        <time_frame>Pre-dose Day 1 and Day 10</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under The Plasma Concentration - Time Curve Over the Dosing Interval (AUC([Tau]) - Part A and C</title>
          <description>AUC(tau) was defined as the area under the plasma concentration - time curve over the dosing interval.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Nanogram*hour/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1151.062" spread="32.2"/>
                    <measurement group_id="O2" value="2869.626" spread="21.3"/>
                    <measurement group_id="O3" value="5132.951" spread="21.5"/>
                    <measurement group_id="O4" value="10088.23" spread="23.1"/>
                    <measurement group_id="O5" value="17057.26" spread="29"/>
                    <measurement group_id="O6" value="21872.72" spread="27"/>
                    <measurement group_id="O7" value="10936.9" spread="29.9"/>
                    <measurement group_id="O8" value="26753.74" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2720.237" spread="20.7"/>
                    <measurement group_id="O2" value="5168.553" spread="23.6"/>
                    <measurement group_id="O3" value="11751.82" spread="15.1"/>
                    <measurement group_id="O4" value="22984.83" spread="17.2"/>
                    <measurement group_id="O5" value="39341.11" spread="24.2"/>
                    <measurement group_id="O6" value="44182.4" spread="27"/>
                    <measurement group_id="O7" value="25556.64" spread="20.4"/>
                    <measurement group_id="O8" value="53972.71" spread="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under The Plasma Concentration - Time Curve Over the Dosing Interval (AUC[Tau]) - Part B</title>
        <description>AUC(tau) was defined as the area under the plasma concentration - time curve over the dosing interval.</description>
        <time_frame>Pre-dose Day 1 and Day 28</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under The Plasma Concentration - Time Curve Over the Dosing Interval (AUC[Tau]) - Part B</title>
          <description>AUC(tau) was defined as the area under the plasma concentration - time curve over the dosing interval.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Nanogram*hour/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12147.23" spread="15.2"/>
                    <measurement group_id="O2" value="12954.8" spread="26.2"/>
                    <measurement group_id="O3" value="24478.35" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31406.32" spread="31.7"/>
                    <measurement group_id="O2" value="34225.08" spread="30.6"/>
                    <measurement group_id="O3" value="59915.72" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Index (AI): Part A and C</title>
        <description>Accumulation index was calculated by dividing the AUC(tau) or Cmax or C24 of BMS-955176 on Day 10 by the AUC(TAU) or Cmax or C24, respectively, of BMS-955176 on Day 1.</description>
        <time_frame>Baseline and Day 10</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Index (AI): Part A and C</title>
          <description>Accumulation index was calculated by dividing the AUC(tau) or Cmax or C24 of BMS-955176 on Day 10 by the AUC(TAU) or Cmax or C24, respectively, of BMS-955176 on Day 1.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.152" spread="42.9"/>
                    <measurement group_id="O2" value="1.674" spread="31.1"/>
                    <measurement group_id="O3" value="2.018" spread="39.8"/>
                    <measurement group_id="O4" value="1.856" spread="33.6"/>
                    <measurement group_id="O5" value="2.135" spread="16.6"/>
                    <measurement group_id="O6" value="1.854" spread="22.7"/>
                    <measurement group_id="O7" value="1.966" spread="17.2"/>
                    <measurement group_id="O8" value="1.771" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.336" spread="21.9"/>
                    <measurement group_id="O2" value="1.757" spread="35"/>
                    <measurement group_id="O3" value="2.11" spread="29.5"/>
                    <measurement group_id="O4" value="2.491" spread="24.9"/>
                    <measurement group_id="O5" value="2.385" spread="25.1"/>
                    <measurement group_id="O6" value="2.063" spread="19.3"/>
                    <measurement group_id="O7" value="2.298" spread="28.4"/>
                    <measurement group_id="O8" value="1.953" spread="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.363" spread="25.9"/>
                    <measurement group_id="O2" value="1.801" spread="30.4"/>
                    <measurement group_id="O3" value="2.289" spread="39.7"/>
                    <measurement group_id="O4" value="2.278" spread="28.2"/>
                    <measurement group_id="O5" value="2.306" spread="19"/>
                    <measurement group_id="O6" value="2.02" spread="19.7"/>
                    <measurement group_id="O7" value="2.337" spread="26.1"/>
                    <measurement group_id="O8" value="2.017" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Body Clearance: Part A and C</title>
        <description>Apparent total body clearance was derived by non-compartmental methods, using a validated pharmacokinetic (PK) analysis program: KineticaTM 5.0 within eToolbox (version 2.7).</description>
        <time_frame>Baseline (Day 1) to Day 10</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance: Part A and C</title>
          <description>Apparent total body clearance was derived by non-compartmental methods, using a validated pharmacokinetic (PK) analysis program: KineticaTM 5.0 within eToolbox (version 2.7).</description>
          <population>Pharmacokinetic Population.</population>
          <units>Milliliters/minute</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.635" spread="18.3"/>
                    <measurement group_id="O2" value="32.246" spread="28"/>
                    <measurement group_id="O3" value="28.364" spread="15.5"/>
                    <measurement group_id="O4" value="29.005" spread="18.8"/>
                    <measurement group_id="O5" value="33.892" spread="23.8"/>
                    <measurement group_id="O6" value="45.267" spread="34"/>
                    <measurement group_id="O7" value="26.086" spread="21.3"/>
                    <measurement group_id="O8" value="37.056" spread="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Degree of Fluctuation (DF): Part A and C</title>
        <description>DF was calculated as the difference between Cmax and Cmin divided by Css-avg. DF was derived by non-compartmental methods, using a validated pharmacokinetic (PK) analysis program: KineticaTM 5.0 within eToolbox (version 2.7).</description>
        <time_frame>Baseline (Day 1) to Day 10</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Fluctuation (DF): Part A and C</title>
          <description>DF was calculated as the difference between Cmax and Cmin divided by Css-avg. DF was derived by non-compartmental methods, using a validated pharmacokinetic (PK) analysis program: KineticaTM 5.0 within eToolbox (version 2.7).</description>
          <population>Pharmacokinetic Population.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.766" spread="29.4"/>
                    <measurement group_id="O2" value="0.912" spread="15.2"/>
                    <measurement group_id="O3" value="0.758" spread="20.2"/>
                    <measurement group_id="O4" value="0.78" spread="22.1"/>
                    <measurement group_id="O5" value="0.779" spread="28.5"/>
                    <measurement group_id="O6" value="0.818" spread="17.1"/>
                    <measurement group_id="O7" value="0.723" spread="13.7"/>
                    <measurement group_id="O8" value="0.727" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Observed Plasma Concentration at Steady State (Css-avg): Part A and C</title>
        <description>Css-avg was calculated by the quotient of AUC(TAU) and the dosing interval (24 h). Css-avg was derived by non-compartmental methods, using a validated pharmacokinetic (PK) analysis program: KineticaTM 5.0 within eToolbox (version 2.7).</description>
        <time_frame>Baseline (Day 1) to Day 10</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Observed Plasma Concentration at Steady State (Css-avg): Part A and C</title>
          <description>Css-avg was calculated by the quotient of AUC(TAU) and the dosing interval (24 h). Css-avg was derived by non-compartmental methods, using a validated pharmacokinetic (PK) analysis program: KineticaTM 5.0 within eToolbox (version 2.7).</description>
          <population>Pharmacokinetic Population.</population>
          <units>Nanogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.326" spread="20.7"/>
                    <measurement group_id="O2" value="215.111" spread="23.8"/>
                    <measurement group_id="O3" value="489.507" spread="15.1"/>
                    <measurement group_id="O4" value="956.222" spread="17.3"/>
                    <measurement group_id="O5" value="1639.471" spread="24.2"/>
                    <measurement group_id="O6" value="1841.413" spread="27"/>
                    <measurement group_id="O7" value="1065.435" spread="19.9"/>
                    <measurement group_id="O8" value="2256.793" spread="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Half-life: Part A and C</title>
        <description>Half-life of the terminal log-linear phase, (T-half), was calculated as natural logarithm of 2 (ln2)/λ, where λ is the absolute value of the slope of the terminal log-linear phase. T-half was derived by non-compartmental methods, using a validated pharmacokinetic (PK) analysis program: KineticaTM 5.0 within eToolbox (version 2.7).</description>
        <time_frame>Baseline (Day 1) to Day 10</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Half-life: Part A and C</title>
          <description>Half-life of the terminal log-linear phase, (T-half), was calculated as natural logarithm of 2 (ln2)/λ, where λ is the absolute value of the slope of the terminal log-linear phase. T-half was derived by non-compartmental methods, using a validated pharmacokinetic (PK) analysis program: KineticaTM 5.0 within eToolbox (version 2.7).</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.134" lower_limit="25.45" upper_limit="46.45"/>
                    <measurement group_id="O2" value="31.967" lower_limit="23.97" upper_limit="43.02"/>
                    <measurement group_id="O3" value="27.382" lower_limit="24" upper_limit="41.59"/>
                    <measurement group_id="O4" value="33.475" lower_limit="25.79" upper_limit="42.39"/>
                    <measurement group_id="O5" value="29.171" lower_limit="24.32" upper_limit="38.02"/>
                    <measurement group_id="O6" value="34.574" lower_limit="29.01" upper_limit="39.69"/>
                    <measurement group_id="O7" value="31.565" lower_limit="24.39" upper_limit="51.64"/>
                    <measurement group_id="O8" value="35.278" lower_limit="26.65" upper_limit="38.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Grade 3/4 Laboratory Abnormalities From Baseline</title>
        <description>Laboratory abnormalities were determined and graded using the Division of Acquired Immune Deficiency Syndrome (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0, December 2004.</description>
        <time_frame>Day 1 to up to end of the study (Day 42)</time_frame>
        <population>All Treated Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O9">
            <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
            <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O10">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O11">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O12">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O13">
            <title>Placebo Clade B</title>
            <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O14">
            <title>Placebo Clade C</title>
            <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Grade 3/4 Laboratory Abnormalities From Baseline</title>
          <description>Laboratory abnormalities were determined and graded using the Division of Acquired Immune Deficiency Syndrome (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0, December 2004.</description>
          <population>All Treated Subjects Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophils (Absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (Total)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Heart Rate</title>
        <description>Heart rate was measured after the participants had been seated quietly for at least 5 minutes. Criteria used to determine heart rate that are outside of a pre-specified range, where changes from Baseline are based on matched postural positions and are calculated as parameter value - Baseline parameter value: Value &gt;100 and change from Baseline &gt; 30, or Value &lt; 55 and change from Baseline &lt; -15.</description>
        <time_frame>Day 1 to end of the study (Day 42)</time_frame>
        <population>All Treated Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O9">
            <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
            <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O10">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O11">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O12">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O13">
            <title>Placebo Clade B</title>
            <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O14">
            <title>Placebo Clade C</title>
            <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Heart Rate</title>
          <description>Heart rate was measured after the participants had been seated quietly for at least 5 minutes. Criteria used to determine heart rate that are outside of a pre-specified range, where changes from Baseline are based on matched postural positions and are calculated as parameter value - Baseline parameter value: Value &gt;100 and change from Baseline &gt; 30, or Value &lt; 55 and change from Baseline &lt; -15.</description>
          <population>All Treated Subjects Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)</title>
        <description>Participants with out of range ECG intervals were summarized. Criteria used to determine ECG results that are outside of a pre-specified range: PR (milliseconds [msec]): Value &gt;200; QRS (msec): Value &gt;120; QT (msec): Value &gt;500 or change from Baseline &gt;30; corrected QT interval Fridericia's formula (QTcF) (msec): Value &gt;450 or change from Baseline &gt;30.</description>
        <time_frame>Day 1 to end of the study (Day 42)</time_frame>
        <population>All Treated Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O9">
            <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
            <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O10">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O11">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O12">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O13">
            <title>Placebo Clade B</title>
            <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O14">
            <title>Placebo Clade C</title>
            <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)</title>
          <description>Participants with out of range ECG intervals were summarized. Criteria used to determine ECG results that are outside of a pre-specified range: PR (milliseconds [msec]): Value &gt;200; QRS (msec): Value &gt;120; QT (msec): Value &gt;500 or change from Baseline &gt;30; corrected QT interval Fridericia's formula (QTcF) (msec): Value &gt;450 or change from Baseline &gt;30.</description>
          <population>All Treated Subjects Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR &gt; 200 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS &gt; 120 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT &gt; 500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB &gt; 450 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF &gt; 450 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Changes in Physical Examination</title>
        <description>Participants with abnormal changes in physical examination is presented.</description>
        <time_frame>Day 1 to end of the study (Day 42)</time_frame>
        <population>All Treated Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O9">
            <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
            <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O10">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O11">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O12">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O13">
            <title>Placebo Clade B</title>
            <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O14">
            <title>Placebo Clade C</title>
            <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Changes in Physical Examination</title>
          <description>Participants with abnormal changes in physical examination is presented.</description>
          <population>All Treated Subjects Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Height</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body mass index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
        <description>Systolic BP (millimeter of mercury [mmHg]): value &gt;140 and change from Baseline &gt;20, or value &lt;90 and change from Baseline &lt;-20; Diastolic BP (mmHg): value &gt;90 and change from Baseline &gt;10, or value &lt;55 and change from Baseline &lt;-10.</description>
        <time_frame>Day 1 to end of the study (Day 42)</time_frame>
        <population>All Treated Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A-Group 1: BMS-955176 (5 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Part A-Group 2: BMS-955176 (10 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O3">
            <title>Part A-Group 3: BMS-955176 (20 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O4">
            <title>Part A-Group 4: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O5">
            <title>Part A-Group 9: BMS-955176 (80 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O6">
            <title>Part A-Group 10: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O7">
            <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O8">
            <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O9">
            <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
            <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O10">
            <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
            <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
          </group>
          <group group_id="O11">
            <title>Part C-Group 8: BMS-955176 (40 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O12">
            <title>Part C-Group 13: BMS-955176 (120 mg)</title>
            <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O13">
            <title>Placebo Clade B</title>
            <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
          <group group_id="O14">
            <title>Placebo Clade C</title>
            <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
          <description>Systolic BP (millimeter of mercury [mmHg]): value &gt;140 and change from Baseline &gt;20, or value &lt;90 and change from Baseline &lt;-20; Diastolic BP (mmHg): value &gt;90 and change from Baseline &gt;10, or value &lt;55 and change from Baseline &lt;-10.</description>
          <population>All Treated Subjects Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to up to end of the study (Day 42)</time_frame>
      <desc>All Treated Subjects comprised of all participants who had received at least one dose of study medication were analyzed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A-Group 1: BMS-955176 (5 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 5 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="E2">
          <title>Part A-Group 2: BMS-955176 (10 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 10 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="E3">
          <title>Part A-Group 3: BMS-955176 (20 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 20 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="E4">
          <title>Part A-Group 4: BMS-955176 (40 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="E5">
          <title>Part A-Group 9: BMS-955176 (80 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="E6">
          <title>Part A-Group 10: BMS-955176 (120 mg)</title>
          <description>Participants infected with HIV-1 clade B were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10 under fasting condition. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="E7">
          <title>Placebo Clade B</title>
          <description>Participants infected with HIV-1 clade B were treated with matching placebo QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="E8">
          <title>Part B-Group 5: BMS-955176 (40 mg) + Atazanavir</title>
          <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS 955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
        </group>
        <group group_id="E9">
          <title>Part B-Group 6: BMS-955176 (40 mg) + Atazanavir + Ritonavir</title>
          <description>Participants infected with HIV-1 clade B were treated with 40 mg BMS-955176 as oral suspension, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
        </group>
        <group group_id="E10">
          <title>Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine</title>
          <description>Participants infected with HIV-1 clade B were treated with 300 mg tenofovir, 200 mg emtricitabine, 300 mg atazanavir capsules and 100 mg ritonavir tablets, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
        </group>
        <group group_id="E11">
          <title>Part B-Group 12: BMS-955176 (80 mg) + Atazanavir</title>
          <description>Participants infected with HIV-1 clade B were treated with 80 mg BMS-955176 as oral suspension and 400 mg atazanavir (2*200 mg) capsules, QD from Day 1 to Day 28 with breakfast. Participants were evaluated for a total period of 42 days from the day of first dose.</description>
        </group>
        <group group_id="E12">
          <title>Part C-Group 8: BMS-955176 (40 mg)</title>
          <description>Participants infected with HIV-1 clade C were treated with 40 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="E13">
          <title>Part C-Group 13: BMS-955176 (120 mg)</title>
          <description>Participants infected with HIV-1 clade C were treated with 120 mg BMS-955176 as oral suspension, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
        <group group_id="E14">
          <title>Placebo Clade C</title>
          <description>Participants infected with HIV-1 clade C were treated with matching placebo, QD from Day 1 to Day 10. Participants were evaluated for a total period of 24 days from the day of first dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>External ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gonorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

